drugset / Trial / NCT04332107

Azithromycin for COVID-19 Treatment in Outpatients Nationwide

NCT04332107

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This individually randomized telemedicine-based trial aims to evaluate the efficacy of a single dose of azithromycin for prevention of progression of COVID-19 in patients with a recent positive SARS-CoV-2 test who are not currently hospitalized.

Timeline

Start
2020-05-22
Primary completion
2021-03-16
Completion
2021-03-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Azithromycin Small molecule 1.2 g Oral

Indications